First Light Asset Management, LLC Prothena Corp Public LTD CO Transaction History

First Light Asset Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $15.9 Million - $26.2 Million	-643,848 Reduced 59.13%	444,953 $11 Million
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $13.3 Million - $21.5 Million	-411,328 Reduced 27.42%	1,088,801 $39.6 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $532,742 - $867,555	-11,039 Reduced 0.73%	1,500,129 $102 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $1.15 Million - $1.42 Million	-24,431 Reduced 1.59%	1,511,168 $73.2 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $160,261 - $200,135	-3,079 Reduced 0.2%	1,535,599 $92.5 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $10.1 Million - $24.2 Million	-399,505 Reduced 20.61%	1,538,678 $93.3 Million
Q2 2022 Aug 12, 2022	BUY	$22.73 - $39.98 $2.26 Million - $3.98 Million	99,635 Added 5.42%	1,938,183 $52.6 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $6.53 Million - $10.6 Million	215,607 Added 13.28%	1,838,548 $67.2 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $7.3 Million - $12.7 Million	173,447 Added 11.97%	1,622,941 $80.2 Million
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $23.1 Million - $37.7 Million	-478,335 Reduced 24.81%	1,449,494 $103 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $21.8 Million - $58.1 Million	-1,007,878 Reduced 34.33%	1,927,829 $99.1 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $9.67 Million - $24.8 Million	879,254 Added 42.76%	2,935,707 $73.7 Million
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $20.8 Million - $28.7 Million	2,056,453 New	2,056,453 $24.7 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Light Asset Management, LLC with notifications on news.